TY - JOUR
T1 - Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus
T2 - Cross-sectional study in a Korean population
AU - Hwang, Y. C.
AU - Ahn, H. Y.
AU - Kim, W. J.
AU - Park, C. Y.
AU - Park, S. W.
PY - 2012/9
Y1 - 2012/9
N2 - Aims The aim of this study was to investigate whether increased apolipoprotein B/apolipoprotein A-I ratio is associated with Type 2 diabetes mellitus independent of other risk factors for Type 2 diabetes. Methods A total of 70063 subjects (41391 men and 28672 women; mean age 41.5years) who visited the Health Screening Center at Kangbuk Samsung Hospital for a routine medical check-up between January 2009 and December 2009 were enrolled in this study. Results The mean apolipoprotein B/apolipoprotein A-I ratio in the study subjects was 0.66±0.18. The prevalence of Type 2 diabetes increased across the apolipoprotein B/apolipoprotein A-I ratio quartiles (1.0%, 1.6%, 2.9%, and 4.8% for the 1st through 4th quartiles, respectively, P<0.001) and homeostasis model assessment-insulin resistance (HOMA2-IR) also showed an increasing tendency by quartile (P<0.001). The apolipoprotein B/apolipoprotein A-I ratio was correlated with age, adiposity, blood pressure, HOMA2-IR value, fasting glucose levels, and other inflammatory marker, including high-sensitivity C-reactive protein, and lipoprotein (a) levels (all P<0.001). In a multiple logistic regression model, the highest apolipoprotein B/apolipoprotein A-I ratio quartile was associated with Type 2 diabetes, even after controlling for other risk factors for diabetes, such as age, gender, BMI, systolic blood pressure, HOMA2-IR values, high-sensitivity C-reactive protein levels, family history of diabetes, presence of metabolic syndrome, and conventional lipid parameters (odds ratio 1.31; 95% confidence interval 1.17-1.46, P<0.001). Conclusions The apolipoprotein B/apolipoprotein A-I ratio was found to be associated with Type 2 diabetes independent of other risk factors for diabetes and conventional lipid parameters.
AB - Aims The aim of this study was to investigate whether increased apolipoprotein B/apolipoprotein A-I ratio is associated with Type 2 diabetes mellitus independent of other risk factors for Type 2 diabetes. Methods A total of 70063 subjects (41391 men and 28672 women; mean age 41.5years) who visited the Health Screening Center at Kangbuk Samsung Hospital for a routine medical check-up between January 2009 and December 2009 were enrolled in this study. Results The mean apolipoprotein B/apolipoprotein A-I ratio in the study subjects was 0.66±0.18. The prevalence of Type 2 diabetes increased across the apolipoprotein B/apolipoprotein A-I ratio quartiles (1.0%, 1.6%, 2.9%, and 4.8% for the 1st through 4th quartiles, respectively, P<0.001) and homeostasis model assessment-insulin resistance (HOMA2-IR) also showed an increasing tendency by quartile (P<0.001). The apolipoprotein B/apolipoprotein A-I ratio was correlated with age, adiposity, blood pressure, HOMA2-IR value, fasting glucose levels, and other inflammatory marker, including high-sensitivity C-reactive protein, and lipoprotein (a) levels (all P<0.001). In a multiple logistic regression model, the highest apolipoprotein B/apolipoprotein A-I ratio quartile was associated with Type 2 diabetes, even after controlling for other risk factors for diabetes, such as age, gender, BMI, systolic blood pressure, HOMA2-IR values, high-sensitivity C-reactive protein levels, family history of diabetes, presence of metabolic syndrome, and conventional lipid parameters (odds ratio 1.31; 95% confidence interval 1.17-1.46, P<0.001). Conclusions The apolipoprotein B/apolipoprotein A-I ratio was found to be associated with Type 2 diabetes independent of other risk factors for diabetes and conventional lipid parameters.
KW - ApoB/A-I ratio
KW - Apolipoprotein A-I
KW - Apolipoprotein B
KW - Type 2 diabetes mellitus
UR - https://www.scopus.com/pages/publications/84865137953
U2 - 10.1111/j.1464-5491.2012.03622.x
DO - 10.1111/j.1464-5491.2012.03622.x
M3 - Article
C2 - 22356423
AN - SCOPUS:84865137953
SN - 0742-3071
VL - 29
SP - 1165
EP - 1170
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 9
ER -